Akademik Veri Yönetim Sistemi
Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, cilt.26, sa.1, ss.104-110, 2021 (ESCI)
Introduction: Tuberculosis (TB) still continues to be the leading cause of death for Human Immunodeficiency Virus (HIV) infected patients, and it accounts for approximately one of three acquired immunodeficiency syndrome (AIDS) related deaths. The study aimed to analyze clinical and laboratory data of Mycobacterium tuberculosis infection in HIV infected patients. Materials and Methods: Medical records of adult (aged≥ 18 years) HIV infected patients diagnosed and under medical care between January 2005 and November 2018 were obtained and analyzed retrospectively by searching hospital database system.Results: Fifteen patients (4.5%) had TB among the 336 HIV infected patients. There was no statistically significant difference between the age of HIV-infected patients with and without TB disease (38.07 ± 8.48 vs 39.26 ± 11.67; p: 0.697). Diagnosis of TB disease and HIV infection were concurrent during presentation in 9 (60%) patients, while six (40%) patients had a previous history of HIV infection and treatment. Five (83.3%) of 6 patients receiving antiretroviral therapy (ART) had no viral suppression due to non-adherence. Median CD4 T lymphocyte count was 114/mm3 (0-436) at the time of TB diagnosis whereas it was 408/mm3 (1-1734) in those without TB disease at the time of initial HIV infection diagnosis, and the difference was statistically significant (p< 0.05). Odds ratio for CD4 T lymphocyte count less than 200 in HIV infected patients with TB disease was 14.89 (confidence interval 95%: 4.08-54.34). While ten (66.7%) patients had pulmonary involvement, five (33.3%) patients had extrapulmonary involvement. There was no statistically significant difference between the median CD4 T lymphocyte counts of patients with pulmonary involvement (107/mm3, range:0-436) and extrapulmonary involvement (140/mm3, range: 86-259) (p= 0.391). Conclusion: Tuberculosis disease should be considered in patients who have applied at advanced stages of HIV infection or whose virological suppression could not be achieved due to incompatibility with ART treatment.